Former Prime Minister visits 糖心原创vlog's Institute of Neurology project in London

Photo courtesy of UCL | from left to right: Professor Selina Wray, Professor of Molecular Neuroscience at UCL Queen Square Institute of Neurology, David Cameron, President of Alzheimer 鈥s Research UK, Professor Fiona Ducotterd, Chief Scientific Officer at the ARUK UCL Drug Discovery Institute (DDI) and Hilary Evans, CEO of Alzheimer鈥s Research UK
Former Prime Minister and President of Alzheimer鈥檚 Research UK (ARUK), David Cameron, visited UCL recently to observe the impact of the work the charity funds, including the ARUK UCL Drug Discovery Institute and the new world-leading facility for UCL Neuroscience.
Professor Fiona Ducotterd (ARUK UCL Drug Discovery Institute) and Professor Selina Wray (UCL Queen Square Institute of Neurology) led the visit and gave Mr Cameron detailed insights into their group鈥檚 translational research programmes and how the future looks for dementia research.
The group visited the new UCL Neuroscience facility at 256 Grays Inn Road, near Kings Cross, where the labs will move next year. It will be a comprehensive, coordinated neuroscience research hub, offering opportunities for multidisciplinary collaboration across basic and clinical science and drug discovery.
Rt Hon David Cameron, President of Alzheimer鈥檚 Research UK, said: 鈥淒ementia is still one of the biggest challenges we face. It was inspiring to visit the ARUK UCL Drug Discovery Institute and see research funded by Alzheimer鈥檚 Research UK in action. Seeing the work first-hand, I鈥檓 more encouraged than ever that we are making huge leaps forward in dementia research.
鈥淩ecent breakthroughs, such as donanemab and lecaneab, show that we can make progress in slowing the disease and what can be achieved when we invest properly in research and infrastructure.
"The new neuroscience centre at Grays Inn Road will play a pivotal role in meeting the challenge on dementia that I set out as Prime Minister, with space to bring expertise from multiple partners, including ARUK-funded teams and initiatives, together under one roof. We can build on the brilliant work that has happened so far, understand more about the broader causes and enable earlier detection of the disease."
Rt Hon David Cameron, President, Alzheimer鈥檚 Research UK
The new centre will house up to 1,000 scientists, clinicians and patients together and enable advances to translate from bench to bedside and back again. As well as seven floors of shared labs, workspaces, consulting rooms and collaboration spaces for scientists and support teams, the building will host an MRI suite with five scanners, a 220-seat lecture theatre and a range of shared core facilities, equipment and core technology platforms including microscopy, transcriptomics and tissue processing to encourage new ways of working, collaboration and knowledge-exchange.
Professor Alan Thompson, Dean, Faculty of Brain Sciences and ION-DRI Programme Sponsor, said: 鈥淚t鈥檚 over ten years since UCL first approached David Cameron as Prime Minister to co-ordinate a national response to begin to tackle neurological diseases, like dementia, which are now the world鈥檚 leading cause of disability.
鈥淚t鈥檚 fantastic to see what has already been achieved since then: We鈥檙e now home to the national headquarters of the UK Dementia Research Institute (UK DRI), which is the single biggest investment the UK has ever made in dementia and are just one year away from opening our new centre of excellence for neuroscience on Grays Inn Road.
鈥淚鈥檓 delighted that David Cameron, in his role now as President of our close partner Alzheimer鈥檚 Research UK, could come back to see how much has been accomplished and feel inspired about what the future holds.鈥
The purpose-built, state-of-the-art neuroscience centre is set to open in 2024.
This was first published on the UCL website and can be